Abstract Objectives People with bipolar disorder (BD) spend more time depressed than manic/hypomanic, and depression is associated with greater impairments in psychosocial functioning and
Abstract Background: Psilocybin, the primary psychoactive component of psychedelic ‘magic mushrooms’, may have potential for treating depressive symptoms, and consequent applications for bipolar disorder
Abstract Acute and enduring adverse effects of psilocybin have been reported anecdotally, but have not been well characterized. For this study, 1993 individuals (mean
©2023 Unlimited Sciences. All rights reserved.
Our newsletter is meant to provide you with the latest news in psychedelic research, inform you about our work, and inspire you with compelling stories from all over the world about the power of psychedelics.
